AARD Aardvark Therapeutics, Inc.

NASDAQ
$6.54

Aardvark Therapeutics, Inc. (AARD) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.73 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.5% since its last earnings release on August 11, 2026.

Aardvark Therapeutics Beat Consensus Estimates
Tuesday, August 11, 2026 · 4:53 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · After Close
Earnings Whisper
-
vs ($0.73)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.51

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow